Illinois Eye Center doctors are proud to be involved in clinical research studies. Our mission is to advance the science of medicine. Our dedicated medical professionals respect our research participants and pride themselves on providing accurate information. We have participated in many studies over the years and are currently enrolling patients in studies. We are proud to partner with sponsor companies to lead the way in the future of medicine. All patients who participate in clinical trials are compensated for their time and travel.

What is a Clinical Trial?

The purpose of clinical trials is to give medical knowledge and research to help treat, diagnose, and possibly prevent a condition. Clinical research involves using human volunteers, and each clinical trial has a list of inclusion and exclusion criteria. Our providers will perform a history and exam to determine if you are a candidate for one of our clinical trials.

Open and Enrolling Trials:


UBX1325 may work to remove aging cells from the body which are thought to no longer function properly. It is believed that these aging cells accumulate and contribute to the pathology associated with wet age-related macular degeneration (wet AMD)

About the Study

How: Either UBX1325 or aflibercept (standard of care treatment) is injected in the eye.

Eligibility: If you are 50 years of age or older, diagnosed with wet AMD, and previously treated with at least 2 anti-VEGF injections, you may be eligible to participate in the study

No Additional Cost: Study Treatments and assessments will be paid for by your participation including transportation to and from the clinic and a stipend will will be provided for your time and commitment. Speak to the Study Coordinator to learn more. identifier: NCT05275205

Illinois Eye Center Research- Past Trial Participation:

AXIS- Glaucoma, Latanoprost vs Xalatan Topical Medicated Solution, Dr. Rhode; 2001

LEED- Open Angle Glaucoma/Ocular Hypertension, Intraocular Pressure Topical Medication Comparison, Dr. Rhode; 2001

XOHT- Ocular Hypertension, Safety and Efficacy of a Topical Medicated Solution, Dr. Rhode; 2003

FOVISTA- Subfoveal Neovascular Age-Related Macular Degeneration, Dr. Han & Dr. P Lagouros; 2015

QRK207- Acute Nonarteritic Anterior Ischemic Optic Neuropathy, Intravitreal Medication Injection, Dr. Han & Dr. P Lagouros; 2016

ACACIA- Diabetic Macular Edema, Safety and Efficacy of AbiCipar, Dr. Han & Dr. P Lagouros; 2017

ISTENT- Glaucoma, Intraocular Implant vs Selective Laser Trabeculoplasty, Dr. Rhode & Dr. E Lagouros; 2018

IDOSE- Glaucoma, Intraocular Medicated Implant vs Topical Medicated Solution, Dr. Rhode, Dr. E Lagouros; 2018

XEN-45- Glaucoma, Gel Intraocular Stent vs Trabeculectomy Procedure, Dr. Rhode & Dr. E Lagouros; 2018

CHAMP- Childhood Myopia Progression, Dr. Pike & Dr. E Lagouros; 2019

GATHER 2- Geographic Atrophy Secondary to Age-Related Macular Degeneration, Intravitreal Medication Injection, Dr. Han; Dr. Eyler; 2020

NICOX–470 – Glaucoma, Intraocular Pressure Topical Medication Comparison, Dr. Rhode, Dr. E Lagouros; 2021

4th of July Holiday Hours

Saturday 7/2 – Peoria Office by Appointment Only
All Other Offices Closed

Monday 7/4 – All Offices Closed